Narrative review highlights mechanistic gaps and limited efficacy in chronic inducible urticaria treatment options.
New Hope for Chronic Hives Targets Specific Triggers
This narrative review examines chronic inducible urticaria (CIndU), focusing on H1-antihistamines, omalizumab, anti-KIT biologics, and BTK i…
New medicines are being built to fix the exact reason your hives appear, moving away from a one-size-fits-all approach.
Retrospective case series evaluates omalizumab efficacy in Chinese pediatric chronic spontaneous urticaria patients.
This Hives Medicine Might Help Young Children Finally Find Relief
This retrospective case series assessed omalizumab in 13 Chinese children under 12 years with chronic spontaneous urticaria. Specific effica…
A common hives drug shows promise for younger kids who usually have few options.
Machine learning model predicts omalizumab efficacy duration in moderate-to-severe perennial allergic rhinitis patients.
A smart model that predicts how long your allergy shot will last
This retrospective cohort study evaluated predictors of omalizumab efficacy duration in 561 patients with moderate-to-severe perennial aller…
A new computer model can estimate how long a popular allergy shot will keep working for each person, making treatment more personal.